Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition
Jianguo Zhuang(University of Liverpool), Andrew R. Pettitt(University of Liverpool)
Cited by 73
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
|New England Journal of Medicine|2023|155
<scp>NCRI</scp> phase <scp>II</scp> study of <scp>CHOP</scp> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
|British Journal of Haematology|2016|66
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2025|26